Suppr超能文献

蛋白酶激活受体 2:胰腺疾病的基石。

PAR2: The Cornerstone of Pancreatic Diseases.

机构信息

Department of Pathology and Molecular Medicine, Third Medical Faculty, Charles University and Thomayer University Hospital, Prague, Czech Republic. petr.suhaj@ftn.

出版信息

Physiol Res. 2022 Nov 28;71(5):583-596. doi: 10.33549/physiolres.934931. Epub 2022 Sep 8.

Abstract

It has been 30 years since the first member of the protease-activated receptor (PAR) family was discovered. This was followed by the discovery of three other receptors, including PAR2. PAR2 is a G protein-coupled receptor activated by trypsin site-specific proteolysis. The process starts with serine proteases acting between arginine and serine, creating an N-terminus that functions as a tethered ligand that binds, after a conformational change, to the second extracellular loop of the receptor, leading to activation of G-proteins. The physiological and pathological functions of this ubiquitous receptor are still elusive. This review focuses on PAR2 activation and its distribution under physiological and pathological conditions, with a particular focus on the pancreas, a significant producer of trypsin, which is the prototype activator of the receptor. The role in acute or chronic pancreatitis, pancreatic cancer, and diabetes mellitus will be highlighted.

摘要

自发现第一个蛋白酶激活受体(PAR)家族成员以来,已经过去了 30 年。随后又发现了另外三个受体,包括 PAR2。PAR2 是一种 G 蛋白偶联受体,可被胰蛋白酶特异性蛋白水解激活。该过程始于丝氨酸蛋白酶在精氨酸和丝氨酸之间的作用,产生一个 N 端作为连接配体,在构象变化后与受体的第二个细胞外环结合,从而激活 G 蛋白。这个普遍存在的受体的生理和病理功能仍然难以捉摸。这篇综述重点介绍了 PAR2 的激活及其在生理和病理条件下的分布,特别关注了胰腺,胰腺是胰蛋白酶的重要产生者,也是该受体的原型激活剂。还将重点介绍其在急性或慢性胰腺炎、胰腺癌和糖尿病中的作用。

相似文献

1
PAR2: The Cornerstone of Pancreatic Diseases.
Physiol Res. 2022 Nov 28;71(5):583-596. doi: 10.33549/physiolres.934931. Epub 2022 Sep 8.
2
Mapping transmembrane residues of proteinase activated receptor 2 (PAR) that influence ligand-modulated calcium signaling.
Pharmacol Res. 2017 Mar;117:328-342. doi: 10.1016/j.phrs.2016.12.020. Epub 2016 Dec 16.
3
Protease-activated receptor-2 exerts contrasting model-specific effects on acute experimental pancreatitis.
J Biol Chem. 2008 Jul 25;283(30):20703-12. doi: 10.1074/jbc.M801779200. Epub 2008 May 28.
8
Proteinase-activated receptor-2: physiological and pathophysiological roles.
Curr Med Chem Cardiovasc Hematol Agents. 2003 Mar;1(1):61-72. doi: 10.2174/1568016033356715.
9
Protein kinase D and Gβγ mediate sustained nociceptive signaling by biased agonists of protease-activated receptor-2.
J Biol Chem. 2019 Jul 5;294(27):10649-10662. doi: 10.1074/jbc.RA118.006935. Epub 2019 May 29.

引用本文的文献

1
Trypsin in pancreatitis: The culprit, a mediator, or epiphenomenon?
World J Gastroenterol. 2024 Nov 7;30(41):4417-4438. doi: 10.3748/wjg.v30.i41.4417.
2
SerpinB3: A Multifaceted Player in Health and Disease-Review and Future Perspectives.
Cancers (Basel). 2024 Jul 18;16(14):2579. doi: 10.3390/cancers16142579.
3
1-Piperidine Propionic Acid as an Allosteric Inhibitor of Protease Activated Receptor-2.
Pharmaceuticals (Basel). 2023 Oct 18;16(10):1486. doi: 10.3390/ph16101486.
4
Circumferential Stenosis of the Second Part of the Duodenum Caused by Eosinophilic Gastroenteritis.
Intern Med. 2024 Apr 15;63(8):1087-1092. doi: 10.2169/internalmedicine.2464-23. Epub 2023 Sep 1.

本文引用的文献

1
Chronic Pancreatitis.
N Engl J Med. 2022 Mar 3;386(9):869-878. doi: 10.1056/NEJMcp1809396.
2
Pancreatic stellate cells - rising stars in pancreatic pathologies.
Physiol Res. 2021 Dec 30;70(Suppl4):S597-S616. doi: 10.33549/physiolres.934783.
3
PAR2 blockade reverses osimertinib resistance in non-small-cell lung cancer cells via attenuating ERK-mediated EMT and PD-L1 expression.
Biochim Biophys Acta Mol Cell Res. 2022 Jan;1869(1):119144. doi: 10.1016/j.bbamcr.2021.119144. Epub 2021 Sep 30.
4
5
The development of proteinase-activated receptor-2 modulators and the challenges involved.
Biochem Soc Trans. 2020 Dec 18;48(6):2525-2537. doi: 10.1042/BST20200191.
6
Heterotrimeric G Protein Subunit Gαq Is a Master Switch for Gβγ-Mediated Calcium Mobilization by Gi-Coupled GPCRs.
Mol Cell. 2020 Dec 17;80(6):940-954.e6. doi: 10.1016/j.molcel.2020.10.027. Epub 2020 Nov 16.
7
Targeting of protease activator receptor-2 (PAR-2) antagonist FSLLRY-NH2 as an asthma adjuvant therapy.
Medicine (Baltimore). 2020 Oct 23;99(43):e22351. doi: 10.1097/MD.0000000000022351.
8
Chronic pancreatitis.
Lancet. 2020 Aug 15;396(10249):499-512. doi: 10.1016/S0140-6736(20)31318-0.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验